British pharma company announces two deals that could double its revenue
British pharmaceutical company, BTG, has announced two deals that could result in the establishment of an interventional medicine business with sales of $1 billion. BTG has agreed to buy Nordion Inc. for close to $200 million, as well as EKOS Corp. for $180 million. The two purchases will add new technology to BTG’s chemotherapy unit and new treatment for severe blood clots.
Read More